Opendata, web and dolomites

iProg

Tailored cell-based therapies for frontotemporal dementia and related genetically defined CNS orphan indications

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 iProg project word cloud

Explore the words cloud of the iProg project. It provides you a very rough idea of what is the project "iProg" about.

restores    systemic    orphan    pgrn    desired    negligible    medical    combat    repair    solutions    iia    sinfonia    leverage    severe    modifying    diseases    prepare    lay    locally    thereby    instrument    neurotrophic    generation    degeneration    patients    market    successful    paving    failing    therapies    brd    medicine    sme    candidates    framework    safety    transforming    implantable    proprietary    game    right    overcome    innovation    indications    cns    safe    conduct    unmet    signals    biotherapeutics    brain    patient    phasei    device    lower    driver    first    causative    disease    biotechnology    lives    tech    detect    frame    therapy    vision    ftd    changers    gene    levels    company    treatment    entirely    disorders    neurodegenerative    therapeutic    genetically    iprog    ultimately    biologics    efficacy    progranulin    manner    frontotemporal    situ    drug    standards    explore    mutations    ing    reaching    clinical    efficacious    populations    exposure    suffer   

Project "iProg" data sheet

The following table provides information about the project.

Coordinator
SINFONIA BIOTHERAPEUTICS AB 

Organization address
address: HALSOVAGEN 7, NOVUM
city: HUDDINGE
postcode: 141 57
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Sweden [SE]
 Project website https://www.sinfoniabiotherapeutics.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2018
 Duration (year-month-day) from 2018-12-01   to  2019-05-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    SINFONIA BIOTHERAPEUTICS AB SE (HUDDINGE) coordinator 50˙000.00

Map

 Project objective

Sinfonia Biotherapeutics is a high-tech biotechnology company. Our vision is to become a main driver in technology innovation for CNS medicine, where we lay the frame-work for entirely novel therapeutic concepts and solutions that combat the unmet medical need of severe CNS conditions, ultimately transforming patient lives. We are developing targeted therapies for genetically defined CNS orphan indications that are built on a proprietary medical device – the Brain Repair Device - that overcome several of the existing challenges associated with the failing clinical development of drug candidates for neurodegenerative diseases today. The BRD is an implantable device that allows for the in situ production of our therapeutic biologics resulting in desired CNS exposure, while the systemic exposure of the therapeutic factor is negligible. We are developing a new generation of tailored biologics for genetically defined disease/patient populations that target the disease locally in the brain. With our therapies we are thus reaching the right patient, with the right treatment, in an efficacious and safe manner. Through the SME Instrument, we will focus on further developing iProg, a novel neurotrophic therapy that restores progranulin levels in the brain of patients that suffer from frontotemporal degeneration due to mutations in the PGRN gene (FTD/PGRN), which results in lower progranulin production and is disease-causative. We will use the SME Instrument funding (Phase 1&2) to prepare and conduct PhaseI/IIa studies to explore the safety and detect the first signals of efficacy of iProg. If successful, the project will set new standards on the biologics for neurodegenerative disease market, paving a way to growth and new potential partnerships for Sinfonia. Our disease-modifying therapies have the potential to leverage an important framework for therapeutic development in neurodegenerative disorders in general and thereby to become real game changers in CNS medicine.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IPROG" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IPROG" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

DetectInMen (2019)

Infection detection in human semen

Read More  

LOLAS (2019)

Precise and reliable autonomous landing for drones, helicopters and other rotorcraft

Read More  

ALR4000 (2019)

Automated LCD Recycling series 4000

Read More